Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584660 | 1.00 | POLB (0.56) | POLBP2RX7RXFP1KMT2ABTK | |
| SCHEMBL24422923 | 1.00 | POLB (0.56) | POLBP2RX7RXFP1KMT2ABTK | |
| SCHEMBL2470608 | 0.85 | POLB (0.64) | POLBP2RX7RXFP1KMT2AACKR3 | |
| SCHEMBL30298771 | 0.83 | CHRM1 (0.65) | POLBP2RX7RXFP1KMT2AACKR3 | |
| Formic Acid SCHEMBL5071431 | 0.80 | POLB (0.59) | POLBP2RX7RXFP1KMT2ABTK | |
| SCHEMBL30298761 | 0.80 | POLB (0.54) | POLBP2RX7RXFP1KMT2ABTK | |
| SCHEMBL29584918 | 0.79 | POLB (0.61) | POLBP2RX7RXFP1KMT2AACKR3 | |
| SCHEMBL24423083 | 0.77 | KMT2A (0.63) | POLBP2RX7RXFP1KMT2AACKR3 | |
| SCHEMBL7309411 | 0.74 | HTR2C (0.67) | POLBP2RX7RXFP1F2MAPT | |
| SCHEMBL19974823 | 0.74 | RXFP1 (0.57) | POLBP2RX7RXFP1KMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| CN-116635380-A | PPARgamma modulators and methods of use | 卫材R&D管理有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
| WO-2022099144-A1 | ΡΡΑRγ MODULATORS AND METHODS OF USE | Eisai R&D Mangement Co., Ltd. (JP) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | POLB 992/4885P2RX7 594/4885RXFP1 572/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | POLB 2032/4885P2RX7 627/4885RXFP1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.